



BioMarker
STRATEGIES

News Release

Contact:

Scott Allocco, President

410-522-1008

sallocco@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

January 22, 2010

***BioMarker Strategies Names Christy Wyskiel to Board of Directors and
Doubles Lab Space at Johns Hopkins Science + Technology Park***

Baltimore, Md—January 22, 2010—BioMarker Strategies announced today that it has elected Christy Williams Wyskiel, a former Managing Director at Maverick Capital, to become a Member of its Board of Directors. The company also announced that it has signed a letter of intent with the Forest City/New East Baltimore Partnership to double its laboratory space at the Johns Hopkins Science+ Technology Park in East Baltimore and extend its lease for two years.

“We are extremely pleased to have a Board Member with Christy’s strong credentials on our Board,” said Karen Olson, CEO of BioMarker Strategies. “Her skills as an equity analyst and investment banker will be very helpful as we position our company for additional rounds of investment.”

As a former Managing Director at Maverick Capital, Ms. Wyskiel was a member of their healthcare team where she managed health care industry investments in the medical device, diagnostics, life sciences, therapeutics and hospital supply industries. And, as a former Member of the Board of Directors of Cardiovascular Systems, she also has previous Board experience.

Prior to joining Maverick, she was a life sciences equity analyst at T. Rowe Price, SG Cowen Securities, and JP Morgan. At Cowen, she participated in all aspects of transaction execution, including financial analysis, performance of financial and company due diligence, creation of offering prospectuses, and accompanying clients to investor road shows. She also performed numerous public and private company valuations. She is also a graduate of Williams College and the Stern School of Business at NYU, where she obtained an MBA in finance and accounting.

In addition to developing the novel SnapPath™ biomarker testing system, BioMarker Strategies is developing an ex vivo biomarker test to help guide the use of targeted cancer therapeutics in patients with advanced solid tumor-based cancers, such as breast, colon, lung and pancreatic cancer. This past summer, the company raised \$1.7 million from private investors, including the Abell Foundation. In the fall, the company was also awarded up to \$2.3m from the National Cancer Institute to expedite the development of the SnapPath™ system. The company was one of the first commercial biotech tenants at the Johns Hopkins Science + Technology Park. For more information about BioMarker Strategies, please go to www.biomarkerstrategies.com.

#

News Release

Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.

#